Patents by Inventor David L. Burgoyne

David L. Burgoyne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12242706
    Abstract: A three-dimensional preview of content can be generated and presented at an electronic device in a three-dimensional environment. The three-dimensional preview of content can be presented concurrently with a two-dimensional representation of the content in a content generation environment presented in the three-dimensional environment. While the three-dimensional preview of content is presented in the three-dimensional environment, one or more affordances can be provided for interacting with the one or more computer-generated virtual objects of the three-dimensional preview. The one or more affordances may be displayed with the three-dimensional preview of content in the three-dimensional environment. The three-dimensional preview of content may be presented on a three-dimensional tray and the one or more affordances may be presented in a control bar or other grouping of controls outside the perimeter of the tray and/or along the perimeter of the tray.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: March 4, 2025
    Assignee: Apple Inc.
    Inventors: David A. Lipton, Ryan S. Burgoyne, Michelle Chua, Zachary Z. Becker, Karen N. Wong, Eric G. Thivierge, Mahdi Nabiyouni, Eric Chiu, Tyler L. Casella
  • Publication number: 20250011293
    Abstract: Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.
    Type: Application
    Filed: February 28, 2024
    Publication date: January 9, 2025
    Applicant: Naegis Pharmaceuticals Inc.
    Inventors: David L. Burgoyne, Erin DeBruin, Julia Fonarev, James Gee Ken Yee, John Michael Langlands
  • Patent number: 11976052
    Abstract: Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: May 7, 2024
    Assignee: Naegis Pharmaceuticals Inc.
    Inventors: David L. Burgoyne, Erin DeBruin, Julia Fonarev, James Gee Ken Yee, John Michael Langlands
  • Publication number: 20220064132
    Abstract: Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.
    Type: Application
    Filed: January 10, 2020
    Publication date: March 3, 2022
    Applicant: Naegis Pharmaceuticals Inc.
    Inventors: David L. Burgoyne, Erin Debruin, Julia Fonarev, James Gee Ken Yee, John Michael Langlands
  • Patent number: 7459479
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: December 2, 2008
    Assignee: Biolipox AB
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen
  • Publication number: 20080287522
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Application
    Filed: July 21, 2008
    Publication date: November 20, 2008
    Applicant: BIOLIPOX AB
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen
  • Patent number: 7446129
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: November 4, 2008
    Assignee: Biolipox AB
    Inventors: Ronald W Lauener, David L Burgoyne, Patrick J Rebstein, Lloyd F Mackenzie, Yuanlin Zhou, Yaping Shen
  • Patent number: 7067682
    Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: June 27, 2006
    Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of Alberta
    Inventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H L Chau, Edward Piers, Hassan Salari
  • Patent number: 6982329
    Abstract: Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding ?,?-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the ?,?-unsaturated ketone structure is efficiently converted to the corresponding vicinal diol using a hydroborating reagent followed by oxidative workup, e.g., borane followed by sodium perborate. Benzoyl and substituted benzoyls are superior protecting groups for hydroxyl groups present in the compounds.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: January 3, 2006
    Assignee: Inflazyme Pharmaceuticals Ltd.
    Inventors: David L. Burgoyne, Gueijun Ji, Eugene W. Kelleher, Nicholas D. Paschalides, Kishore Ramachandran, Yaping Shen, Yuanlin Zhou
  • Patent number: 6949533
    Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6? and 7? oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6? and 7? oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and ?-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: September 27, 2005
    Assignees: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of Alberta
    Inventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
  • Publication number: 20040266744
    Abstract: Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding &agr;, &bgr;-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the &agr;, &bgr;-unsaturated ketone structure is efficiently converted to the corresponding vicinal diol using a hydroborating reagent followed by oxidative workup, e.g., borane followed by sodium perborate. Benzoyl and substituted benzoyls are superior protecting groups for hydroxyl groups present in the compounds.
    Type: Application
    Filed: July 15, 2004
    Publication date: December 30, 2004
    Inventors: David L Burgoyne, Yaping Shen, Gueijun Ji, Yuanlin Zhou, Kishore D. Ramachandran, Nicholas D. Paschalides, Eugene W. Kelleher
  • Publication number: 20040162425
    Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
    Type: Application
    Filed: November 6, 2003
    Publication date: August 19, 2004
    Applicants: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of Alberta
    Inventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
  • Publication number: 20040157814
    Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
    Type: Application
    Filed: November 6, 2003
    Publication date: August 12, 2004
    Applicants: Inflazyme Pharmaceuticals Ltd., The University of British Columbia, The University of Alberta
    Inventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.L. Chau, Edward Piers, Hassan Salari
  • Patent number: 6770658
    Abstract: &ggr;-Phenyl-substituted &Dgr;-lactams are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: August 3, 2004
    Assignee: Inflazyme Pharmaceuticals Ltd.
    Inventors: Yaping Shen, David L. Burgoyne, Ronald W. Lauener, Yuanlin Zhou, Patrick J. Rebstein, Samuel D. M. Abraham
  • Publication number: 20040138486
    Abstract: Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding &agr;,&bgr;-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the &agr;,&bgr;-unsaturated ketone structure is efficiently converted to the corresponding vicinal diol using a hydroborating reagent followed by oxidative workup, e.g., borane followed by sodium perborate. Benzoyl and substituted benzoyls are superior protecting groups for hydroxyl groups present in the compounds.
    Type: Application
    Filed: December 22, 2003
    Publication date: July 15, 2004
    Applicant: Inflazyme Pharmaceuticals Ltd.
    Inventors: David L. Burgoyne, Gueijun Ji, Eugene W. Kelleher, Nicholas D. Paschalides, Kishore Ramachandran, Yaping Shen, Yuanlin Zhou
  • Patent number: 6706701
    Abstract: Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have oxygen substitution at C6 and C7, and some have specific stereochemistries such as 6&agr; and 7&bgr; oxygen substitution, and an alpha hydrogen at the 5 position in addition to having 6&agr; and 7&bgr; oxygen substitution. Steroids having 3,4-epoxy functionality are also disclosed. In addition, steroids having C17 pyran and &dgr;-lactone functionality, with oxygen substitution at C6 and C7, or at C15, of the steroid nucleus, are disclosed.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: March 16, 2004
    Assignees: Inflazyme Pharmaceuticals Ltd., University of British Columbia, University of Alberta
    Inventors: David L. Burgoyne, Yaping Shen, John M. Langlands, Christine Rogers, Joseph H.-L. Chau, Edward Piers, Hassan Salari
  • Patent number: 6696580
    Abstract: Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding &agr;,&bgr;-unsaturated ketone using copper iodide and t-butyl hydroperoxide. A steroid compound containing the &agr;,&bgr;-unsaturated ketone structure is efficiently converted to the corresponding vicinal diol using a hydroborating reagent followed by oxidative workup, e.g., borane followed by sodium perborate. Benzoyl and substituted benzoyls are superior protecting groups for hydroxyl groups present in the compounds.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: February 24, 2004
    Assignee: Inflazyme Pharmaceuticals Ltd.
    Inventors: David L. Burgoyne, Gueijun Ji, Eugene W. Kelleher, Nicholas D. Paschalides, Kishore Ramachandran, Yaping Shen, Yuanlin Zhou
  • Publication number: 20030220352
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Application
    Filed: March 18, 2003
    Publication date: November 27, 2003
    Applicant: Inflazyme Pharmaceuticals Ltd.
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. MacKenzie, Yuanlin Zhou, Yaping Shen
  • Publication number: 20030186943
    Abstract: &ggr;-Phenyl-substituted &Dgr;-lactams are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.
    Type: Application
    Filed: October 1, 2002
    Publication date: October 2, 2003
    Applicant: Inflazyme Pharmaceuticals Ltd.
    Inventors: Yaping Shen, David L. Burgoyne, Ronald W. Lauener, Yuanlin Zhou, Patrick J. Rebstein, Samuel D. M. Abraham
  • Patent number: 6555572
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: April 29, 2003
    Assignee: Inflazyme Pharmaceuticals Ltd.
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen